In clinical practice, how can AMD imaging biomarkers guide risk stratification and shape discussions with patients regarding prognosis and monitoring?

When I see a patient with intermediate AMD, if I see biomarkers on OCT such as hyperreflective foci (HRF), drusen that have hyporeflective cores, lots of drusenoid deposits, acquired vitelliform lesions, or areas of thick basal laminar deposit, I realize that patient is at higher risk for progression and so I see them at shorter intervals e.g., q3-4 months depending on how many of these are present. If these are too many to remember, I would at least look for HRF.